La cardiomiopatía dilatada canina: reflexiones , retos y expectativasdiscurso de apertura del curso 2019

Referencias bibliográficas

• Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270-6.
• Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report–2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34:1244-54.
• Meurs KM, Miller MW, Wright NA. Clinical features of dilated cardiomyopathy in Great Danes and results of a pedigree analysis: 17 cases (1990–2000). J Am Vet Med Assoc. 1998;218: 729-32.
• Distl O, Vollmar AC, Broschk C, et al. Complex segregation analysis of dilated cardiomyopathy (DCM) in Irish wolfhounds. Heredity. 2007;99:460-5.
• McKenna WJ, Maron BJ, Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circ Res. 2017;121:722-30.
• Tidholm A, Svensson H, Sylven C. Survival and prognostic factors in 189 dogs with dilated cardiomyopathy. J Am Anim Hosp Assoc. 1997:33:364-8.
• Tidholm A, Häggström J, Borgarelli M, et al. Canine idiopathic dilated cardiomyopathy. Part I: aetiology, clinical characteristics, epidemiology and pathology. Vet J. 2001;162:92-107.
• Tidholm A, Jonsson L. Dilated cardiomyopathy in the Newfoundland: a study of 37 cases. J Am Anim Hosp Assoc. 1996;32:465-70
• Calvert CA, Meurs KM. Cardiomyopathy in Doberman Pinschers In: Bonagura JD, Twedt DC eds. Current veterinary therapy. St. Louis: Saunders Elsevier; 2009:800-3.
• Calvert CA, Jacobs GJ, Smith DD, et al. Association between results of ambulatory electrocardiography and development of cardiomyopathy during long-term follow-up of Doberman Pinschers. J Am Anim Hosp Assoc. 2000:216:34-39.
• Dukes-McEwan J, Borgarelli M, Tidholm A, et al. The ESVC Taskforce for Canine Dilated Cardiomyopathy. Proposed guidelines for the diagnosis of canine idiopathic dilated cardiomyopathy. J Vet Cardiol. 2003:5;7-19
• Egenvall A, Bonnett BN, Häggström J. Heart disease as a cause of death in insured swedish dogs younger than 10 years of age. J Vet Intern Med. 2006;20:894-903.
• Tidholm A, Jonsson L. A retrospective study of canine dilated cardiomyopathy (189 cases). J Am Anim Hosp Assoc. 1997;33: 544-50.
• Mausberg TB, Wess G, Simak J. et al. A locus on chromosome 5 is associated with dilated cardiomyopathy in doberman pinschers. PLoS ONE. 2011;6:e20042
• Karlsson EK, Lindblad-Toh K. Leader of the pack: gene mapping in dogs and other model organisms. Nat Rev Genet. 2008;9:713-25.
• Wilbe M, Jokinen P, Truvé K, et al. Genome-wide association mapping identifies multiple loci for a canine SLE-related disease complex. Nat Genet. 2010;42:250-4.
• Maron BJ, Towbin JA, Thiene G, et al. American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Science.... 2006;113:1807-16.
• Falk R, Hershberger RE. The dilated, restrictive, and infiltrative cardiomyopathies. In Mann DL, Ziper DP, Libby P, et al. (Eds.): Braunwald's heart disease. A textbook of cardiovascular medicine. 10th ed. Philadelphia, Elsevier Saunders, 2015, p. 1551-1573.
• Fleming JM, Creevy KE, Promislow DEL. Mortality in north american dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death. J Vet Intern Med. 2011;25:187-98.
• Tidholm A, Häggström J, Borgarelli M, et al. Canine idiopathic dilated cardiomyopathy. Part I: aetiology, clinical characteristics, epidemiology and pathology. Vet J. 2001;162:92-107
• Guttmann OP, Mohiddin SA, Elliott PM Almanac 2014: Cardiomyopathies. Heart. 2014;100:756-64.
• Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850e8
• O'Grady MR, O'Sullivan ML. Dilated cardiomyopathy: an update. Vet Clin Small Anim Pract. 2004;34:1187-207.
• Prosek R. (2014). Dilated Cardiomyopathy. American College of Veterinary Internal Medicine. Disponible en el URL: http://www.acvim.org/Animal-Owners/Animal- Education/Health-Fact- Sheets/Cardiology/Dilated-Cardiomyopathy
• Martin MW, Stafford Johnson MJ, Strehlau G, et al. Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases. J Small Anim Pract. 2010;51:428-36.
• Meurs KM, Magnon AL, Spier AW, et al. Evaluation of the cardiac actin gene in Doberman pinschers with dilated cardiomyopathy. Am J Vet Res. 2001;62:33-6.
• Meurs KM, Spier AW, Hamlin RL, et al. Use of ambulatory electrocardiography for detection of ventricular premature complexes in healthy dogs. J Am Vet Med Assoc. 2001;218:1291-2.
• Meurs KM, Spier AW, Wright NA, et al. Comparison of inhospital versus 24-hour ambulatory electrocardiography for detection of ventricular premature complexes in mature boxers. J Am Vet Med Assoc. 2001;218:222-4.
• Calvert CA, Pickus CW, Jacobs GJ, et al. Signalment, survival, and prognostic factors in doberman pinschers with end-stage cardiomyopathy. J Vet Intern Med. 1997;11:323-6.
• Calvert CA. Dilated congestive cardiomyopathy in doberman pinschers. Comp Cont Educ Pract. 1986;8:417-30.
• Calvert CA, Hall G, Jacobs G, et al. Clinical and pathologic findings in Doberman pinschers with occult cardiomyopathy that died suddenly or developed congestive heart failure: 54 cases (1984–1991). J Am Vet Med Assoc. 1997;210:505-11.
• Brownlie SE, Cobb MA. Observations on the development of congestive heart failure in Irish wolfhounds with dilated cardiomyopathy. J Small Anim Pract. 1999;40:371-7.
• Wess G, Schulze A, Butz V, et al. Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups. J Vet Intern Med. 2010;24:533-8
• O’Grady MR. Doberman Pinschers: Lessons learned in the first decade of study. Proceedings 20th ACVIM Forum. 2002;114-5.
• Harpster N. Boxer cardiomyopathy. Vet Clin North Am Small Anim Pract. 1991;21:989-1004.
• Fioretti M, Delli Carri E. Epidemiological survey of dilatative cardiomyopathy in dogs. Abstract Veterinaria. 1988;2:81.
• Sisson D, O'Grady MR, Calvert CA. Myocardial diseases of dogs. En: Fox PR, Sisson D, Moïse NS. Textbook of canine and feline cardiology. WB Saunders Company, Philadelphia. 1999:581-620.
• Ettinger SJ, Feldman EC, Cote E. Veterinary Internal Medicine. 8th Edition. St Louis Missouri Elsevier, 2017
• Stephenson HM, Fonfara S, López-Alvarez J, et al. Screening for dilated cardiomyopathy in Great Danes in the United Kingdom. J Vet Intern Med. 2012;26:1140-7.
• Vollmar AC. The prevalence of cardiomyopathy in the Irish wolfhound: a clinical study of 500 dogs. J Am Anim Hosp Assoc. 2000;36:125-32.
• The COVE STUDY GROUP. Controlled Clinical Evaluation of Enalapril in Dogs With Heart Failure: Results of the Cooperative Veterinary Enalapril Study Group. J Vet Intern Med. 1995;9:243-52
• Garcia-Pavia P, Cobo-Marcos M, Guzzo-Merello G, et al. Geneticsin dilated cardiomyopathy. Biomark Med. 2013;7:517-33.
• McNally EM, Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res. 2017;121:731-48
• Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 2010;12:655-67.
• Simpson S, Edwards J, Emes RD, et al. A predictive model for canine dilated cardiomyopathy-a meta-analysis of Doberman Pinscher data. Peer J. 2015;3:e842.
• Simpson S, Edwards J, Ferguson-Mignan FTN, et al. Genetics of human and canine dilated cardiomyopathy. Int J Genom. 2015;2015:204823.
• Simpson S, Dunning MD, Brownlie S, et al. Multiple Genetic Associations with Irish Wolfhound Dilated Cardiomyopathy. Biomed Res Int. 2016;2016:6374082
• Simpson S, Rutland P, Rutland CS. Genomic Insights into Cardiomyopathies: A Comparative Cross-Species Review. Vet Sci. 2017;4:19.
• Meurs KM, Lahmers S, Keene BW, et al. A splice site mutation in a gene encoding for pdk4, a mitochondrial protein, is associated with the development of dilated cardiomyopathy in the Doberman pinscher. Hum Genet. 2012;131:1319-25.
• Philipp U, Vollmar A, Haggstrom J, et al. Multiple loci are associated with dilated cardiomyopathy in Irish wolfhounds. PLos ONE. 2012;7:e36691
• Meurs KM, Stern JA, Sisson DD, et al. Association of dilated cardiomyopathy with the striatin mutation genotype in boxer dogs. J Vet Intern Med. 2013;27:1437-40
• Schatzberg SJ, Olby NJ, Breen M, et al. Molecular analysis of a spontaneous dystrophin ‘knockout’ dog. Neuromuscular Disorders. 1999;9:289-95.
• Kittleson MD, Keene BW, Pion P, et al. Results of the multicenter spaniel trial (MUST): Taurine- and carnitine-responsive dilated cardiomyopathy in American Cocker Spaniels with decreased plasma taurine concentration. J Vet Intern Med. 1998;11:204-11.
• Kittleson, M. Kienle, R. Small animal cardiovascular medicine. Mosby, St Louis, USA. 2000.
• Sanderson SL. Taurine and carnitine in canine cardiomyopathy.Vet Clin North Am Small Anim Pract. 2006;36:1325-43.
• Keene BW, Kittleson MD, Rush JE, et al. Myocardial carnitine deficiency associated with dilated cardiomyopathy in Doberman pinschers. Abstract. J Vet Intern Med. 1989:3;126.
• Keene B, Panciera DP, Atkins CE, et al. Myocardial L-carnitine deficiency in a family of dogs with dilated cardiomyopathy. J Am Vet Med Assoc. 1991;198:647-50.
• McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest. 2013; 123:19-26.
• Calvert CA, Brown J. Use of M-mode echocardiography in the diagnosis of congestive cardiomyopathy in Doberman pinschers. J Am Vet Med Assoc. 1986;189:293-7
• Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. Am J Cardiol. 1992;69:1458-66.
• Calvert CA, Jacobs G, Pickus CW, et al. Results of ambulatory electrocardiography in overtly healthy Doberman Pinschers with echocardiographic abnormalities. J Am Vet Med Assoc. 2000;217:1328-32.
• O’Grady MR, Horne R. Occult dilated cardiomyophaty: an echocardiographic and electrocardiographic study of 193 asymptomatic Doberman pinschers. Abstract. J Vet Intern Med. 1992;6:112.
• O’Grady MR, Horne R. Occult dilated cardiomyopathy: an echocardiographic and electrocardiographic study of 193 asymptomatic Doberman pinschers. In: 15th Annual Veterinary Medical Forum 1995. p. 298-99
• Calvert CA, Chapman WL, Toal RL. Congestive cardiomyopathy in Doberman pinscher dogs. J Am Vet Med Assoc. 1982;181:598-602.
• Hazlett MJ, Maxie MG, Allen DG, et al. A retrospective study of heart disease in Doberman Pinscher dogs. Can Vet J. 1983;24: 205-10.
• Proschowsky HF, Rugbjerg H, Ersbøll AK. Mortality of purebred and mixed-breed dogs in Denmark. Preventive Veterinary Medicine. 2003;58:63-74.
• Domanjko-Petric A, Stabej P, Zemva A (2002) Dilated cardiomyopathy in the Dobermann dog: survival, causes of death and a pedigree review in a related line. J Vet Cardiol. 2002:4:17-24.
• Fuentes VL, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med. 2002;16:255-61.
• O´Grady MR, Minors SL, O´Sullivan ML, et al. Effect of pimobendan on case fatality rate in doberman pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med. 2008;22:897-904.
• Petric AD, Stabej P, Zemva A. Dilated cardiomyopathy in Doberman Pinschers: survival, causes of death and a ped- igree review in a related line. J Vet Cardiol. 2002;4:17-24.
• Meurs KM, Fox PR, Norgard MM, et al. A prospective genetic evaluation of familial dilated cardiomyopathy in the Doberman pinscher. J Vet Intern Med. 2007;21:1016-21.
• Philipp U, Broschk C, Vollmar A, et al. Evaluation of tafazzin as candidate for dilated cardiomyopathy in Irish wolfhounds. J Hered. 2007;98:506-509
• Phillip U, Vollmar A, Distl O. Evaluation of six genes for dilated cardiomyopathy in Irish wolfhounds. Anim Genet. 2007;39:84- 92.
• Phillip U, Vollmar A, Distl O. Evaluation of the titin-cap (TCAP) as candidate for dilated cardiomyopathy in Irish wolfhounds. Anim Biotechnol. 2008;19:231-6.
• O'Sullivan ML, O'Grady MR, Pyle WG, et al. Evaluation of 10 genes encoding cardiac proteins in Doberman Pinschers with dilated cardiomyopathy. Am J Vet Res. 2011;72:932-9.
• Stabej P, Imholz A, Versteeg S A, et al. Characterization of the canine desmin (DES) gene and evaluation as a candidate gene for dilated cardiomyopathy in the Dobermann. Gene. 2004;340:241-9.
• Stabej P, Leegwater PA, Imholz S, et al. The canine sarcoglycan delta gene: BAC clone contig assembly, chromosome assignment and interrogation as a candidate gene for dilated cardiomyopathy in Doberman dogs. Cytogenet Genome Res. 2005;111:140-6.
• Stabej P, Leegwater PA, Stokhof AA, et al. Evaluation of the phospholamban gene in purebred large-breed dogs with dilated cardiomyopathy. Am J Vet Res. 2005;66:432-6.
• Wiersma AC, Leegwater PA, van Oost BA, et al. Canine candidate genes for dilated cardiomyopathy: annotation of and polymorphic markers for 14 genes. BMC Vet Res. 2007;3:28.
• Wiersma AC, Stabej P, Leegwater PAJ, et al. Evaluation of 15 candidate genes for dilated cardiomyopathy in the Newfoundland dog. J Hered. 2008;99:73-80.
• Spier AW, Meurs KM, Coovert DD, et al. Use of western immunoblot for evaluation of myocardial dystrophin, α- sarcoglycan, and β-dystroglycan in dogs with idiopathic dilated cardiomyopathy. Am J Vet Res. 2001; 62: 67-71.
• Meurs KM, Ederer M, Stern J. Evaluation of five desmosomal genes in Boxer arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res. 2007;68:1338-41.
• Meurs KM, Hendrix KP, Norgard MM. Molecular evaluation of five cardiac genes in Doberman pinschers with dilated cardiomyopathy. Am J Vet Res. 2008;68:1050-3.
• Meurs KM, Mauceli E, Acland G, et al. Genomewide association identifies a mutation for arrhythmogenic right ventricular cardiomyopathy in the Boxer. Proc ACVIM. 2009:864e865
• Meurs KM, Norgard MM, Kuan M, et al. Analysis of 8 sarcomeric candidate genes for feline hypertrophic cardiomyopathy mutations in cats with hypertrophic cardiomyopathy. J Vet Intern Med. 2009;23:840-3.
• Meurs KM, Mauceli E, Lahmers S, et al. Genome-wide association identifies a mutation in the 3’ untranslated region of striatin, a desmosomal gene, in a canine model of arrhythmogenic right ventricular cardiomyopathy. Hum Genet. 2010;20:315-24.
• Meurs KM, Stern JA, Reina Doreste Y, et al. Natural history of arrhythmogenic right ventricular cardiomyopathy in the boxer dog: a prospective study. J Vet Intern Med. 2014;28:1214-20.
• Wynn RM, Kato M, Chuang JL, et al. Pyruvate dehydrogenase kinase-4 structure reveal a metastable open conformation fostering robust core-free basal activity. J Biol Chem. 2010;12:25305-15.
• Lopaschuk GD, Ussher JR, Folmes CDL, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90: 207-58.
• Saddik M, Gamble J, Witters LA, et al. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem. 1993;268:25836-45.
• Sandusky GE Jr, Capen CC, Kerr KM. Histological and ultrastructural evaluation of cardiac lesions in idiopathic cardiomyopathy in dogs. Can J Comp Med. 1984;48:81-6.
• McCutcheon LJ, Cory CR, Nowack L, et al. Respiratory chain defect of myocardial mitochondria in idiopathic dilated cardiomyopathy of Doberman pinscher dogs. Can J Physiol Pharmacol. 1992;70:1529-33.
• Lei B, Lionetti V, Young ME, et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol. 2011;36:567-76.
• Neubauer S, Krahe T, Schindler R, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810-8.
• O'Brien PJ, O'Grady M, McCutcheon LJ, et al. (1992) Myocardial myoglobin deficiency in various animal models of congestive heart failure. J Mol Cell Cardiol. 1992;24:721-30.
• O'Brien PJ. Deficiencies of myocardial troponin-T and creatine kinase MB isoenzyme in dogs with idiopathic dilated cardiomyopathy. Am J Vet Res. 1997;58:11-6.
• Tamargo J, Delpón E. Pharmacologic bases of antiarrhythmic therapy. Chapter 54. En: Cardiac Electrophysiology. 8th Edition. Eds. Zipes DP, Jalife J, Stevenson WG. Elsevier. Philadelphia. 2017. pp. 513-524.
• Owczarek-Lipska M, Mausberg T-B, Stephenson H, et al. A 16- bp deletion in the canine PDK4 gene is not associated with dilated cardiomyopathy in a European cohort of Doberman Pinschers. Animal Genetics. 2013;44:121-239.
• Owczarek-Lipska M, Mausberg TB, Stephenson H, et al. A 16- bp deletion in the canine PDK4 gene is not associated with dilated cardiomyopathy in a European cohort of Doberman Pinschers. Anim Genet. 2013;44:239.
• Hoey A. Canine dilated cardiomyophathy -are there defects at the receptor level? Abstract. Proceedings, British Small Anim Veterinary Medical Association, 1991, p. 142.
• Harpster NK. Boxer Cardiomyopathy. Kirk R, editor. Ed. Current Veterinary Therapy. VIII. Philadelphia: WB Saunders, 1983, pp. 329-337.
• Baumwart RD, Meurs KM, Atkins CE, et al. Clinical, echocardiographic, and electrocardiographic abnormalities in Boxers with cardiomyopathy and left ventricular systolic dysfunction: 48 cases (1985–2003) J Am Vet Med Assoc. 2005;226:1102-4.
• Palermo V, Stafford Johnson MJ, et al. Cardiomyopathy in Boxer dogs: a retrospective study of the clinical presentation, diagnostic findings and survival. J Vet Cardiol Off J Eur Soc Vet Cardiol. 2011;13:45-55.
• Nader M, Alotaibi S, Alsolme E, et al. Cardiac striatin interacts with caveolin-3 and calmodulin in a calcium sensitive manner and regulates cardiomyocyte spontaneous contraction rate. Can J Physiol Pharmacol. 2017;95:1306-12.
• Dukes-McEwan J, Jackson IJ. The promises and problems of linkage analysis by using the current canine genome map. Mamm Genome. 2002;13:667-72.
• Wang J, Bingaman S, Huxley VH. Intrinsic sex-specific differences in microvascular endotelial cell phosphodiesterases. Am J Physiol Heart Circ Physiol. 2010;298:H1146-54
• Pyle RL, Patterson DF, Chacko S. The genetics and pathology of discrete subaortic stenosis in the Newfoundland dog. Am Heart J. 1976;92:324-34.
• Oyama MA, Chittur S, Reynolds CA. Decreased triadin and increased calsatbin2 expression in Great Danes with dilated cardiomyopathy. J Vet Intern Med. 2009; 23:1014-9.
• Oyama MA, Chittur S. Genomic expression patterns of cardiac tissues from dogs with dilated cardiomyopathy. Am J Vet Res. 2005;66:1140-55.
• Dambach DM, Lannon A, Sleeper MM, et al. Familial dilated cardiomyopathy of Young Portuguese water dogs. J Vet Intern Med. 1999;13:65-71.
• Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. J. Am. Med. Assoc. 2006;296:1867-76.
• Werner P, Raducha MG, Prociuk U, et al. A novel locus for dilated cardiomyopathy maps to canine chromosome 8. Genomics. 2008;91:517-21.
• Schatzberg S. J., Olby N. J., Breen M., et al. Molecular analysis of a spontaneous dystrophin ‘knockout’ dog. Neuromuscular Disorders. 1999;9(5):289-295.
• Tamargo J, Delpón E. Generalidades del aparato cardiovascular. La célula cardiaca. En: Fisiología Humana. Ed. Tresguerres J, Ariznavarreta C, Cachofeiro V, Cardinali D, Escrich E, Gil-Loyzaga P, Lahera V, Mora F, Romano M, Tamargo J. Ed. McGraw Hill-Interamericana. 4ª Edición. México 2010:486-496
• Tamargo J, Delpón E. La función de bomba del corazón: el ciclo cardiaco. En: Fisiología Humana. Ed. Tresguerres J, Ariznavarreta C, Cachofeiro V, Cardinali D, Escrich E, Gil- Loyzaga P, Lahera V, Mora F, Romano M, Tamargo J. Ed. McGraw Hill- Interamericana. 4ª Edición. México 2010:522-541
• Tamargo J, Delpón E. Sección V: Aparato circulatorio. Farmacología de la insuficiencia cardiaca I. Glucósidos digitálicos y otros inotrópicos. En: Farmacología Humana (6ª edición). Ed.: Jesús Flórez. Elsevier Masson. Barcelona 2013:581-594.
• Tamargo J, Delpón E. Sección V: Aparato circulatorio. Farmacología de la insuficiencia cardiaca II. Fármacos diuréticos, vasodilatadores e inhibidores neurohumorales. En: Farmacología Humana (6ª edición). Ed.: Jesús Flórez. Elsevier Masson. Barcelona 2013:595-605.
• Tidholm A, Jonsson L. Histologic characterization of canine dilated cardiomyopathy. Vet Pathol. 2005; 42:1-8.
• Aupperle H, Marz I, Baldauf K, et al. Pathology of DCM in Great Danes. J Veterinary Internal Medicine. 2014;28:730.
• Lobo L, Carvalheira J, Canada N, et al. Histologic characterization of dilated cardiomyopathy in Estrela mountain dogs. Vet Pathol. 2010;47:637-42.
• Calvert CA, Jacobs GJ, Kraus M, et al. Signal-averaged electrocardiograms in normal Doberman pinschers. J Vet Intern Med. 1998;12:355-64.
• Calvert CA, Jacobs GJ. Heart rate variability in Doberman Pinschers with and without echocardiographic evidence of dilated cardiomyopathy. Am J Vet Res. 2000;61:506-11.
• Calvert CA, Brown J. Influence of antiarrhythmia therapy on survival times of 19 clinically healthy Doberman pinschers with dilated cardiomyopathy that experienced syncope, ventricular tachycardia, and sudden death (1985–1998). J Am Anim Hosp Assoc. 2004;40:24-28.
• Singletary GE, Morris NA, Lynne O'Sullivan M, et al. Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers. J Vet Intern Med. 2012;26:1330-6.
• Wess G, Simak J, Mahling M, et al. Cardiac troponin I in Doberman Pinschers with cardiomyopathy. J Vet Intern Med. 2010;24:843-9.
• Rush JE, Keene BW. ECG of the month. The sudden death of a dog with dilatative cardiomyopathy. J Am Vet Med Assoc. 1989;194:52-3.
• Calvert CA, Meurs K. Doberman pinscher occult cardiomyopathy. In: Bonagura JD, Kirk RW, editors. Current Veterinary Therapy XIII. Philadelphia: W. B. Saunders; 2000. pp. 756-760.
• Meurs KM. Boxer dog cardiomyopathy: an update. Vet Clin North Am Small Anim Pract. 2004;34:1235-44.
• Ynaraja E, Ynaraja E, Morales M. Bases de la cardiología canina. Colección Textos Universitarios. Gobierno de Canarias. Ed Litografía A Romero S.A. Tenerife. 2001.
• Ynaraja E, Ynaraja E. Manual clínica de cardiología básica en el perro y en el gato.Ed. Servet Diseño y Comunicación S.L. Zaragoza 2005.
• Wess G, Schulze A, Geraghty N, et al. Ability of a 5-minute electrocardiography (ECG) for predicting arrhythmias in Doberman Pinschers with cardiomyopathy in comparison with a 24- hour ambulatory ECG. J Vet Intern Med. 2010;24:367-71.
• Calvert CA, Jacobs GJ, Kraus M. Possible ventricular late potentials in Doberman pinschers with occult cardiomyopathy. J Am Vet Med Assoc. 1998;213:235-9.
• Stern JA, Meurs KM, Spier AW, et al. Ambulatory electrocardiographic evaluation of clinically normal adult Boxers. J Am Vet Med Assoc. 2010;236:430-3
• Motskula PF, Linney C, Palermo V, et al. Prognostic value of 24-hour ambulatory ECG (Holter) monitoring in Boxer dogs. J Vet Intern Med. 2013;27:904-12.
• Meurs KM, Spier AW, Miller MW, et al. Familial ventricular arrhythmias in boxers. J Vet Intern Med. 1999;13:437-9.
• Toivonen L. Spontaneous variability in the frequency of ventricular premature complexes over prolonged intervals and implica tions for antiarrhythmic treatment. Am J Cardiol. 1987;60:608-12.
• Wess G, Domenech O, Dukes-Ewan J, et al. European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers. J Vet Cardiol. 2017;19:405-1
• Klüser L, Holler PJ, Simak J, et al. Predictors of sudden cardiac death in doberman pinschers with dilated cardiomyopathy. J Vet Intern Med. 2016;30:722-32
• Kraus MS, Thomason JD, Fallaw TL, et al. Toxicity in Doberman Pinchers with ventricular arrhythmias treated with amiodarone (1996–2005). J Vet Intern Med. 2009;23:1-6.
• Wess G, Butz V, Mahling M, et al. Evaluation of N-terminal pro- B-type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman Pinschers. Am J Vet Res. 2011;72:642-9.
• Winter RL, Saunders AB, Gordon SG, Buch JS, Miller MW. Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease. J Vet Cardiol. 2017;19:124-31.
• Oyama MA, Boswood A, Connolly DJ, et al. Clinical usefulness of an assay for measurement of circulating N-terminal pro-Btype natriuretic peptide concentration in dogs and cats with heart disease. J Am Vet Med Assoc. 2013;243:71-82.
• Jishi F, Hudson PR, Williams CP, Jones et al. Laboratory issues, and clinical outcomes in a district general hospital: crossover study with “traditional” markers of myocardial infarction in a total of 1990 patients. J Clin Pathol. 2004;57:1027e32
• Baumwart RD, Orvalho J, Meurs KM. Evaluation of serum cardiac troponin I concentrations in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res. 2007;68:524-8.
• Payne EE, Roberts BK, Schroeder N, et al. Assessment of a point-of-care cardiac troponin I test to differentiate cardiac from noncardiac causes of respiratory distress in dogs. J Vet Emerg Crit Care San Antonio. 2011;21:217-25.
• Guglielmini C, Civitella C, Diana A, et al. Serum cardiac troponin I concentration in dogs with precapillary and postcapillary pulmonary hypertension. J Vet Intern Med. 2010;24:145-52.
• Fonfara S, Loureiro J, Swift S, et al. Cardiac troponin I as a marker for severity and prognosis of cardiac disease in dogs. Vet J. 2010;184:334-9.
• Burgener IA, Kovacevic A, Mauldin GN, et al. Cardiac troponins as indicators of acute myocardial damage in dogs. J Vet Intern Med. 2006;20:277-83.
• Langhorn R, Oyama MA, King LG, et al. Prognostic Importance of Myocardial Injury in Critically Ill Dogs with Systemic Inflammation. J Vet Intern Med. 2013;27:895-903.
• Hamacher L, Dorfelt R, Muller M, et al. Serum cardiac troponin I concentrations in dogs with systemic inflammatory response syndrome. J Vet Intern Med. 2015;29:164-70
• O’Grady MR, O’Sullivan ML, Minors SL, et al. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009;23:977-83.
• Summerfield NJ, Boswood A, O’Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). J Vet Intern Med. 2012; 26:1337-49
• McEwan JD. Canine dilated cardiomyopathy 2. Pathophysiology and treatment. In Practice. 2000;22:620-8.
• Smith CE, Freeman LM, Rush JE, et al. Omega-3 Fatty Acids in Bóxer Dogs with Arrhythmogenic Right Ventricular Cardiomyopathy. J Vet Intern Med. 2007:21;265-73
• Ware, W. Cardiovascular disease in small animal medicine. Manson publishing. En: Myocardial diseases of the dog. 2007, pp. 280-28.
• Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure therapy—a silver bullet? J Am Anim Hosp Assoc. 2006;42:90-3.
• Boswood A. Current use of pimobendan in canine patients with heart disease. Vet Clin North Am Small Anim Pract. 2010;40:571-80.
• Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio). 2012;22:398-408.
• Chen CH, Nakaya Y, Minami K, et al. Effects of pimobendan and its active metabolite, UD-CG 212 Cl, on Ca2+-activated K+ channels in vascular smooth-muscle cells. J Cardiovasc Pharmacol. 1997;30:739-43.
• Lombard CW, Jöns O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42:249-61.
• Erlemeier HH, Kupper W, Bleifield W. Comparison of hormonal and hemodynamic changes after long-term therapy with pimobendan or enalapril—A double-blind randomised study. Eur Heart J. 1991;12:889-99.
• Sasaki T, Kubo T, Komamura K, et al. Effect of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. J Cardio. 1999;33:317-25.
• Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardio. 1999;33:1400-7
• Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardio. 1999;33:1400-7
• Asanoi H, Ishizaka S, Kameyama T, et al. Disparate inotropic and lusitropic response to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol. 1994; 23:268-74.
• Caballero R, López-Sendón JL, Tamargo J. Capítulo 21. Fármacos con efecto inotrópico positivo. En: Velázquez. Farmacología Básica y Clínica. (19ª edición). Ed. Lorenzo P et al. Buenos Aires; Madrid: Ed. Médica Panamericana 2017:345-357.
• Tamargo J. Sección V: Aparato circulatorio. Fármacos antiarrítmicos. En: Farmacología Humana (6ª edición). Ed.: Jesús Flórez. Elsevier Masson. Barcelona 2013:615-632.
• Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178-186.
• Pouleur H, Hanet C, Schroder E, et al. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol. 1989;14(Suppl 2):S18-S22.
• Smith PJ, French AT, Van Israel N, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract. 2005;46:121-30.
• Lamontagne J, DiFruscia R. Cardiomyophatie dilatee canine: la survie apres le diagnostic. Med Vet Quebec. 1991;21:141
• The IMPROVE Study Group.Acute and short-term hemodynamics, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive Multicenter Prospective Veterinary Evaluation of Enalapril Study. J Vet Int Med. 1995;9:234-42.
• Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc. 1998;213:1573-7.
• BENCH (BENazepril in Canine Heart disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol. 1999;1:7-18.
• Schuller S, Van Israël N, Vanbelle S, et al. Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. J Vet Pharmacol Ther. 2011;34:322-31.
• Bernay F, Bland JM, Häggström J, et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet InternMed. 2010:24,331-41
• Martin MWS, Stafford Johnson MJ, et al. Canine dilated cardiomyopathy: a retrospective study of signalment, presentation and clinical findings in 369 cases. J Small Anim Pract. 2009;50:23-9.
• Monnet E, Orton EC, Salman M, et al. Idiopathic dilated cardiomyopathy in dogs: survival and prognostic indicators. J Vet Intern Med. 1995;9:12-7.
• O'Grady MR, Horne R. The prevalence of dilated cardiomyopathy in doberman pinschers: a 4.5 year follow-up (abstract). J Vet Intern Med. 1998;12:199.
• Wotton PR. Dilated cardiomyopathy (DCM) in closely related Boxers dogs and its possibly resemblance to arrhythmogenic right ventricular cardiomyopathy (ARVC) in humans. Proc 17th Ann Vet Med Forum ACVIM. 1999:88-9
• Philipp U, Vollmar A, Distl O. Evaluation of six candidate genes for dilated cardiomyopathy in Irish wolfhounds. Anim Genetics. 2008;39:88–89.
• Lynne O'Sullivan M, O'Grady MR, Glen Pyle W, et al. Evaluation of 10 genes encoding cardiac proteins in Doberman Pinschers with dilated cardiomyopathy. Am J Vet Res. 2011;72:932- 8.
• Parker HG, Kim LV, Sutter NB, et al. Genetic structure of the purebred domestic dog. Science. 2004;304:1160-4
• Friedenberg SG, Chdid L, Keene B, et al. Use of RNA-seq to identify cardiac genes and gene pathways differentially expressed between dogs with and without dilated cardiomyopathy. Am J Vet Res. 2016;77:693-9.
• Ashrafian H, Docherty L, Leo V, et al. A mutation in the mitochondrial fission gene Dnm1l leads to cardiomyopathy. PLoS Genet. 2010;6:e1001000.
• Sibbing D, Pfeufer A, Perisic T, et al. Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. Eur Heart J. 2011; 32:1121-33
• Zarrouk Mahjoub S, Mehri S, Ourda F, et al. Novel m.15434C >A (p. 230L>I) mitocondrial Cytb gene missense mutation associated with dilated cardiomyopathy. ISRN Cardiol. 2012; 2012:1-6.
• Xu X, Zhang Y, Williams J, et al. Parallel comparison of Illumina RNA-seq and Affymetrix microarray platforms on transcriptomic profiles generated from 5-aza-deoxy-cytidine treated HT- 29 colon cancer cells and simulated datasets. BMC Bioinformatics. 2013;14(Suppl 9):S1.
• Wang C, Gong B, Bushel PR, et al. The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. Nat Biotechnol. 2014; 32:926-932.
• Zhao S, Fung-Leung WP, Bittner A, et al. Comparison of RNAseq and microarray in transcriptome profiling of activated T cells. PLoS One. 2014;9:e78644.